Abrogation of chronic monoclonal antibody treatment-induced T-cell exhaustion with DURVALUMAB (MEDI4736) in advanced HER-2 negative breast cancer: a pilot proof-of-concept trial.

Trial Profile

Abrogation of chronic monoclonal antibody treatment-induced T-cell exhaustion with DURVALUMAB (MEDI4736) in advanced HER-2 negative breast cancer: a pilot proof-of-concept trial.

Active, no longer recruiting
Phase of Trial: Phase 0

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Durvalumab (Primary) ; Bevacizumab
  • Indications Advanced breast cancer
  • Focus Pharmacodynamics; Proof of concept
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Jun 2016 New trial record
    • 13 Jun 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top